3.410EUR+0.47%Mkt Cap: —P/E: —1d ago
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi tha…
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$375.50BUSDP/E 122.7
$341.92BUSDP/E 24.5
$348.81BUSDP/E 25.0
$279.13BUSDP/E 22.3
$274.07BUSDP/E 23.6
$240.45BUSDP/E 24.5
$231.49BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$139.84BUSDP/E 32.2
$138.11BUSDP/E 14.9
Key Statistics
Company
Market Cap—
Enterprise Value70.05M $
Revenue (TTM)2.92M $
Gross Profit2.59M $
Net Income (TTM)-40.97M $
Revenue/Share0.1315 USD
Last Price3.410 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2024
Employees64
CountryGB
SectorHealthcare
Industry—
ISINFR0012127173
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.73
EV/Revenue23.95
P/S—
P/B2.66
EPS (TTM)-0.93
EPS (Forward)—
52W Range
3.29269% of range3.462
52W High3.462 EUR
52W Low3.292 EUR
Profitability
Gross Margin88.70%
Oper. Margin-2272.16%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-82.32%
ROA-23.10%
Growth
Revenue Growth-0.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.99M $
CapEx (TTM)—
FCF Margin-662.85%
FCF Yield—
Net Debt-14.11M $
Net Debt/EBITDA0.35
Balance Sheet
Debt/Equity72.30
Current Ratio1.28
Quick Ratio1.17
Book Value/Sh1.238 EUR
Cash/Share2.513 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.14.61M
Float17.31M
Insiders25.37%
Institutions2.77%
Technical
SMA 504.187 (-18.6%)
SMA 2004.176 (-18.3%)
Beta0.83
S&P 52W Chg20.80%
Avg Vol (30d)3.16K
Avg Vol (10d)2.08K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—